A Phase 2 interventional study of Subcutaneous elamipretide through the elamipretide delivery system and Subcutaneos placebo through the elamipretide delivery system in Age-related Macular Degeneration, sponsored by Stealth BioTherapeutics Inc.. Completed at 37 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 122nd largest by enrollment of the 491 interventional ones that give a count, is one of 32 that started in 2019, is one of 138 in phase 2, and was the 413th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 32 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 5 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.
This was a randomized, double-masked, placebo controlled study using three periods to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy. The total duration of subject participation was up to 54 weeks, including a Screening Period (≤2 weeks), Treatment Period (48 weeks), and Follow-up (4 weeks). 176 eligible subjects were randomized in a 2:1 ratio (elamipretide:placebo) to receive 40 mg elamipretide or placebo. The study drug (i.e., elamipretide or placebo) was administered once daily via SC injection using the elamipretide delivery system during the 48 week Treatment Period. After completion of the 48-week Treatment Period subjects continued to be monitored for safety during the 4-week Follow-up Period and an end of study (EOS) Follow-up Visit was conducted at Week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular conditions-study eye
GA in the study eye at the Screening Visit may be multi-focal, but the cumulative GA lesion and size must:
Systemic and general criteria
Exclusion Criteria:
Ocular conditions-study eye
Ocular conditions--either eye
Systemic conditions.
General
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily 40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
Combination Product: Subcutaneous elamipretide through the elamipretide delivery system
Once daily subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
Combination Product: Subcutaneos placebo through the elamipretide delivery system
Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
Also known as: elamipretide, MTP-131, Bendavia
Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
LL BCVA Score Change From Baseline
Change in low luminance best corrected visual acuity (LL BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
Time frame: Baseline and Weeks 4, 8, 12, 24, 36, 48
GA Area Change From Baseline by OCT
Geographic atrophy (GA) area: change from baseline as measured by optical coherence tomography (OCT) from Baseline to the end of treatment (EOT; Week 48)
Time frame: Baseline and Weeks 12, 24, 36, 48
LL RA Change From Baseline
Low-luminance ready acuity (LL RA) score change from baseline to the EOT (Week 48). Mean Critical Print Size with Low Luminance in Weeks 4, 12, 36, 48 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.
Time frame: Baseline and Weeks 4,12, 36, 48
BCVA Change From Baseline
Best-corrected visual acuity (BCVA) change from Baseline Change in best corrected visual acuity (BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
Time frame: Baseline and Weeks 4, 8, 12, 24, 36, 48
GA Area as Measured by Fundus Autofluorescence (FAF) Change From Baseline
Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.
Time frame: Baseline and Weeks 12, 24, 36, 48
Macular Percentage of Ellipsoid Zone (EZ) Total Attenuation From Baseline
Change from Baseline in Macular Percentage of EZ Total Attenuation by OCT: Week 24 and Week 48 measures photoreceptor loss marked by EZ degradation. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.
Time frame: Baseline, Week 24 and Week 48
| Milestone | Elamipretide | Placebo |
|---|---|---|
| Started | 117 | 59 |
| Completed | 83 | 51 |
| Not completed | 34 | 8 |
| Withdrew: Withdrawal by subject | 20 | 3 |
| Withdrew: Adverse event | 10 | 4 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Covid-19 infection | 1 | 0 |
Change in low luminance best corrected visual acuity (LL BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
| Letters | Elamipretide | Placebo |
|---|---|---|
| Week 4 | 0.7 ± 6.11 | -0.6 ± 5.93 |
| Week 8 | 1.1 ± 5.64 | -0.8 ± 7.71 |
| Week 12 | -0.7 ± 9.35 | -0.9 ± 7.05 |
| Week 24 | -0.9 ± 9.05 | -0.9 ± 6.80 |
| Week 36 | -0.6 ± 12.21 | -3.2 ± 9.37 |
| Week 48 | -2.8 ± 11.40 | -4.6 ± 11.89 |
Geographic atrophy (GA) area: change from baseline as measured by optical coherence tomography (OCT) from Baseline to the end of treatment (EOT; Week 48)
| mm^2 | Elamipretide | Placebo |
|---|---|---|
| Week 12 | 0.082 ± 0.0889 | 0.071 ± 0.0812 |
| Week 24 | 0.166 ± 0.1391 | 0.166 ± 0.1426 |
| Week 36 | 0.245 ± 0.1680 | 0.228 ± 0.1977 |
| Week 48 | 0.328 ± 0.2166 | 0.281 ± 0.2407 |
Low-luminance ready acuity (LL RA) score change from baseline to the EOT (Week 48). Mean Critical Print Size with Low Luminance in Weeks 4, 12, 36, 48 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.
| units on a scale | Elamipretide | Placebo |
|---|---|---|
| Week 4 | -0.005 ± 0.2678 | 0.029 ± 0.3169 |
| Week 12 | -0.008 ± 0.3429 | 0.035 ± 0.3244 |
| Week 36 | 0.002 ± 0.3776 | 0.073 ± 0.2761 |
| Week 48 | 0.011 ± 0.4082 | 0.101 ± 0.3069 |
Best-corrected visual acuity (BCVA) change from Baseline Change in best corrected visual acuity (BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
| Letters | Elamipretide | Placebo |
|---|---|---|
| Week 4 | 0.3 ± 4.03 | -0.1 ± 4.51 |
| Week 8 | 0.0 ± 4.88 | 0.9 ± 4.84 |
| Week 12 | -0.2 ± 4.46 | -0.0 ± 6.14 |
| Week 24 | -0.2 ± 5.09 | -0.2 ± 5.00 |
| Week 36 | -1.5 ± 5.76 | -0.8 ± 6.13 |
| Week 48 | -3.0 ± 6.90 | -2.6 ± 7.86 |
Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.
| mm^2 | Elamipretide | Placebo |
|---|---|---|
| Week 12 | 0.074 ± 0.0690 | 0.065 ± 0.0804 |
| Week 24 | 0.161 ± 0.1218 | 0.138 ± 0.1338 |
| Week 36 | 0.242 ± 0.1659 | 0.199 ± 0.1700 |
| Week 48 | 0.318 ± 0.2060 | 0.277 ± 0.2176 |
Change from Baseline in Macular Percentage of EZ Total Attenuation by OCT: Week 24 and Week 48 measures photoreceptor loss marked by EZ degradation. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.
| percentage of EZ total attentuation | Elamipretide | Placebo |
|---|---|---|
| Week 24 | 1.81 ± 3.889 | 2.70 ± 3.291 |
| Week 48 | 3.94 ± 4.052 | 6.38 ± 6.616 |
Collected over Up to 54 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elamipretide | 2/117 (1.7%) | 18/117 (15.4%) | 83/117 (70.9%) |
| Placebo | 0/59 (0%) | 6/59 (10.2%) | 36/59 (61%) |
| Event | Elamipretide | Placebo |
|---|---|---|
| Corona virus infectionInfections and infestations | 2/117 | 0/59 |
| CholelithiasisHepatobiliary disorders | 2/117 | 0/59 |
| PneumoniaInfections and infestations | 2/117 | 0/59 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/117 | 1/59 |
| Lung carcinoma cell type unspecified stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/117 | 1/59 |
| FallInjury, poisoning and procedural complications | 0/117 | 1/59 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/117 | 1/59 |
| Upper respiratory tract infectionInfections and infestations | 0/117 | 1/59 |
| Pancreatitis acuteGastrointestinal disorders | 0/117 | 1/59 |
| Glomerular filtration rate decreasedRenal and urinary disorders | 0/117 | 1/59 |
| Event | Elamipretide | Placebo |
|---|---|---|
| Injection Site PruritusGeneral disorders | 46/117 | 0/59 |
| Injection Site PainGeneral disorders | 33/117 | 6/59 |
| Injection Site ErythemaGeneral disorders | 22/117 | 0/59 |
| Injection Site BruisingGeneral disorders | 15/117 | 11/59 |
| Injection Site HaemorrhageGeneral disorders | 17/117 | 4/59 |
| Injection Site IndurationGeneral disorders | 16/117 | 3/59 |
| Urinary Tract InfectionInfections and infestations | 4/117 | 7/59 |
| Injection Site MassGeneral disorders | 13/117 | 0/59 |
| Injection Site SwellingGeneral disorders | 11/117 | 0/59 |
| Injection Site HypertrophyGeneral disorders | 10/117 | 4/59 |
All subjects that were randomized and received at least one dose of study drug and have baseline and at least one post-baseline value for LL BCVA or GA Area on OCT.
| Age, Continuous(years) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Mean | 76.0 ± 8.40 | 75.8 ± 8.80 | 76.0 ± 8.51 |
| Sex: Female, Male(Participants) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Female | 68 | 36 | 104 |
| Male | 46 | 22 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 111 | 53 | 164 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Race (NIH/OMB)(Participants) | Elamipretide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 112 | 57 | 169 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Elamipretide | Placebo | Total |
|---|---|---|---|
| United States | 114 | 58 | 172 |
| Body Mass Index(kg/m^2) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Mean | 29.85 ± 6.479 | 27.92 ± 5.380 | 29.20 ± 6.181 |
| GA Area (mm2) by OCT(mm^2) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Mean | 1.47 ± 0.761 | 1.38 ± 0.682 | 1.44 ± 0.734 |
| LL BCVA Score(Letters) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Mean | 53.4 ± 16.17 | 58.8 ± 10.70 | 55.2 ± 14.75 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2019 to primary completion in Feb 2022, 34 months.
Results were first posted in Oct 2023, 1 year 7 months after primary completion.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 34 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →